GRAL Stock Overview
A commercial-stage healthcare company, focuses on developing technologies for early cancer detection in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
GRAIL, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$29.74 |
| 52 Week High | US$63.99 |
| 52 Week Low | US$12.33 |
| Beta | 0 |
| 1 Month Change | -24.25% |
| 3 Month Change | 34.21% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 117.72% |
Recent News & Updates
GRAIL: Cash Burn And Commercialization Timeline Are Problematic
Jan 22Here's Why We're Watching GRAIL's (NASDAQ:GRAL) Cash Burn Situation
Dec 24
Recent updates
GRAIL: Cash Burn And Commercialization Timeline Are Problematic
Jan 22Here's Why We're Watching GRAIL's (NASDAQ:GRAL) Cash Burn Situation
Dec 24Grail: Lack Of Near Term Catalyst; Market Likely To Lose Interest Soon
Dec 16GRAIL: Post-Spinoff, Illumina Maintains Control And Incentive To Support Success
Sep 24GRAIL's Potential Turnaround: Seeking FDA Approval For Galleri
Sep 09Shareholder Returns
| GRAL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.5% | -1.0% | -2.2% |
| 1Y | n/a | -5.2% | 9.5% |
Return vs Industry: Insufficient data to determine how GRAL performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how GRAL performed against the US Market.
Price Volatility
| GRAL volatility | |
|---|---|
| GRAL Average Weekly Movement | 22.3% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.4% |
Stable Share Price: GRAL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GRAL's weekly volatility has increased from 16% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 1,000 | Bob Ragusa | grail.com |
GRAIL, Inc., a commercial-stage healthcare company, focuses on developing technologies for early cancer detection in the United States and internationally. It provides Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company offers development services including support for ongoing clinical studies, pilot testing, research, and therapy development.
GRAIL, Inc. Fundamentals Summary
| GRAL fundamental statistics | |
|---|---|
| Market cap | US$912.46m |
| Earnings (TTM) | -US$2.03b |
| Revenue (TTM) | US$125.60m |
8.0x
P/S Ratio-0.5x
P/E RatioIs GRAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRAL income statement (TTM) | |
|---|---|
| Revenue | US$125.60m |
| Cost of Revenue | US$203.62m |
| Gross Profit | -US$78.02m |
| Other Expenses | US$1.95b |
| Earnings | -US$2.03b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -59.80 |
| Gross Margin | -62.12% |
| Net Profit Margin | -1,613.92% |
| Debt/Equity Ratio | 0% |
How did GRAL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/14 22:09 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GRAIL, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Subhalaxmi Nambi | Guggenheim Securities, LLC |
| Tejas Savant | Morgan Stanley |
| Douglas Schenkel | Wolfe Research, LLC. |